Nevro Corp Stock News

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.

Despite convincing beats on its latest set of quarterly figures, the market wasn't all that impressed with the company's latest developments.

Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.

Nevro Corp. (NVRO) Q4 2023 Earnings Call Transcript

Nevro (NVRO) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.54 per share a year ago.

Nevro's (NVRO) latest announcement of a positive coverage update from Carelon Healthcare for PDN treatment is likely to serve a wider patient pool.

Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.

Nevro Corp.'s stock NVRO, +5.27% rose by 0.3% in premarket trades on Tuesday after the Redwood City, Calif.-based medical device maker said it would reduce its work force by 5% or 63 people.

REDWOOD CITY, Calif. , Jan. 4, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pa

Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.

Nevro's (NVRO) latest acquisition is likely to bring long-term pain relief to people suffering from chronic low back pain associated with the SI joint.

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?

Nevro Corp. shares have significantly underperformed, selling 57% lower than in 2021. The company's top-line momentum continues, but it faces economic challenges and lacks value creation for sharehold

Nevro's (NVRO) HFX Connect system is expected to treat individual patients per their requirements with 35 pre-programmed customizable plans.